The Triple-Agonist Frontier: Why Experts Are Urging Caution Amid the Hype for Retatrutide
The landscape of obesity medicine is undergoing a seismic shift. In recent years, the arrival of GLP-1 receptor agonists—such as semaglutide (Wegovy) and tirzepatide (Zepbound)—has revolutionized how clinicians approach chronic…
